Shots:

• Oncologie to conduct P-II study assessing the efficacy and safety of Bavituximab in combination with Merck’s Keytruda (pembrolizumab) in patients with 1L advanced gastric or gastroesophageal cancer enrolling ~80 patients in the US- UK- Korea and Taiwan with expected enrollment in H2’19
• The focus of the collaboration is to evaluate the combination Keytruda and Bavituximab for getting better insights of cancer further improving QoL
• Bavituximab is a chimeric mAb targeting the activity of phosphatidylserine (PS) and has shown safety and tolerability in multiple clinical trials. Keytruda is a mAb blocking the interaction between PD-1 and its ligands- PD-L1 and PD-L2 and activating the T lymphocytes and is evaluated in 950+ trials for multiple indications

Click here to read full press release/ article

Ref: PRNewswire | Image: Merck